About Lumend
Lumend is a Healthcare company based in Redwood City (United States) founded in 1996 by Matt Selmon and John Simpson, and was acquired by Cordis in September 2005. Catheter-based technologies for crossing chronic vascular occlusions are developed. Lumend has raised $30.05 million across 4 funding rounds from investors including Cordis, CHL Medical Partners and Morgenthaler. The company was acqui-hired. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its competitors include Cardiovascular Systems, Contego Medical and AngioScore; 3 of its 3 listed competitors have raised funding.
Company details
Lumend was founded in 1996 in Redwood City, United States, focusing on medical devices in the cardiovascular sector. Catheter-based technologies are produced and developed to address chronic occlusions in coronary and peripheral artery disease. Devices that aid guide wire placement during invasive procedures, including angioplasty and stenting, are marketed to interventional cardiologists, radiologists, and vascular surgeons. The company was acquired by Cordis in 2005.
- Headquarters Redwood City, United States
- Founders Matt Selmon, John Simpson
- Stage Acquired
- SectorsHealthcare
- Website lumend.com
- Acquired by Cordis (Sep 2005)
Funding Insights of Lumend
Lumend has successfully raised a total of $30.05M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $2 million completed in August 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30.05M
- Total Rounds 4
- Last Round Series D — $2M
- First Round $23M
(Jan 2003)
- Investors Count 6
All 4 funding rounds of Lumend with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2005 | $2M | Series D | – | – | – |
| Jun 2005 | $3.05M | Series D | – | – | – |
| Feb 2005 | $2M | Series D | – | – | – |
| Jan 2003 | $23M | Series D | – | – |
7 investors in total: 7 institutional.
Investors in Lumend
Lumend has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Cordis, CHL Medical Partners and Morgenthaler.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage healthcare services investments are facilitated by CHL. | chlmedical.com | Westport, United States | ||
Venture capital and private equity investment firm | morgenthaler.com | Portola Valley, United States | ||
| denovovc.com | ||||
Venture capital firm | absventures.com | Waltham, United States | ||
Healthcare sector investments are managed through private equity strategies. | pa-investors.com | Palo Alto, United States | ||
Seed & early-stage VC firm investing in the US | tefunds.com | San Mateo, United States | ||
Cardiovascular and endovascular devices are developed and marketed by Cordis. | 1957 | cordis.com | Fremont, United States |
Investor details for Lumend
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Lumend
2 people are tracked at Lumend (2 in leadership).
| Name | Role | Group |
|---|---|---|
Matt Selmon | Co-Founder | Leadership |
John Simpson | Co-Founder | Leadership |
Complete people profiles for Lumend
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Lumend
4 dated milestones of Lumend across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Lumend is founded.
- Funding First funding round of $23.0M.
- Funding Latest funding round, Series D, of $2.0M.
- Exit Acquired by Cordis.
Competitors of Lumend
Lumend has 3 listed competitors in our database, 3 of them funded. They include Cardiovascular Systems, Contego Medical and AngioScore.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| csi360.com | 1989 | Saint Paul, United States | $121.2M | 780 | Devices for treating peripheral and coronary vascular disease are developed. | |
| contegomedical.com | 2005 | Raleigh, United States | $66.01M | Provider of vascular stenting with embolic protection for both coronary and peripheral vasculature | ||
| angioscore.com | 2003 | Fremont, United States | $87M | Scoring balloon catheters for coronary and peripheral angioplasty are developed. |
Detailed competitors of Lumend
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Lumend (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lumend
Complete news archive for Lumend
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lumend
Lumend was founded in 1996 and raised its 1st funding round 7 years after it was founded.
Lumend is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Lumend is a funded company, having raised a total of $30.05M across 4 funding rounds to date. The company's 1st funding round was a Series D of $23M, raised on Jan 2003.
Lumend was founded in 1996 in Redwood City, United States, focusing on medical devices in the cardiovascular sector. Catheter-based technologies are produced and developed to address chronic occlusions in coronary and peripheral artery disease. Devices that aid guide wire placement during invasive procedures, including angioplasty and stenting, are marketed to interventional cardiologists, radiologists, and vascular surgeons. The company was acquired by Cordis in 2005.
Lumend's top competitors include Contego Medical, Cardiovascular Systems and AngioScore.
Lumend has 7 investors. Key investors include Cordis, CHL Medical Partners, Morgenthaler, De Novo Ventures, and ABS Ventures.
Yes. Lumend was acquired by Cordis in September 2005.